Akeso reports another Phase 3 win for PD-1xVEGF approach in lung cancer

Akeso said its PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a Phase 3 study in lung cancer patients in China. The readout marks the third late-stage win for ivonescimab in lung cancer ...